(Date:11/21/2008)...e University College of Medicine research team led...layer of regulation in the cell division cycle, wh...ay cancer begins. , Wang, an assistant professor..., said the findings will lead to an improved abili... of new drugs that kill cancer cells by inhibiting...
(Date:11/21/2008)...ewswire/ -- The Generic,Pharmaceutical Associatio...om,GPhA President and CEO Kathleen Jaeger regardi...on "Emerging Health Care Competition and Consumer ...onducting this roundtable demonstrates the,growin...ess to safe and,affordable biogenerics sooner rat...
(Date:11/21/2008)...USNewswire/ -- New research at West Virginia Univ... tobacco product aimed at young adults is catching...ds, Camel Snus - touted as a socially acceptable w...gh levels of nicotine. , , "Camel Snus cont..." said Bruce Adkins of the state Division of Tobac...
(Date:11/21/2008)...re-FirstCall/ -- Today, prescription drugs are the... 88 percent of patients suffering chronic conditio...onic condition account for 96 percent of all presc...l costs. A proprietary new pharmacy model develop.... (NYSE: MHS ) significantly reduces critical ga...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6(Date:11/19/2008)... Calif., Nov. 19 Amgen,...ogy Company, a subsidiary of,Takeda Pharmaceutica...t,enrollment in the Phase 3 MONET1 trial evaluati...axel and carboplatin for the first-line treatment ...s been temporarily suspended,following a planned ...
(Date:11/19/2008)...illion Payment from Roche- , , MONTVALE, N....aceuticals Corp. (Nasdaq: MEMY ) today announced...Phase 2 trial of R3487/MEM 3454, its lead alpha-7 ...t associated with schizophrenia (CIAS). The Compa...l, triggering a $5.0 million payment from its part...
(Date:11/18/2008)...Association,s 2008 Faces of Influenza survey under... against influenza; Mother and Gold Medalist Krist...N, Nov. 18 While 78 percent of mot...ere and potentially life-threatening disease that ...r families will get vaccinated this season, accord...
(Date:11/12/2008)...Nov. 12 A new study bei...ll will help answer the,question, what causes Park...ons in the medical research into,Parkinson,s disea... to die,in the first place. Answering this questio...two nearly identical types of brain cells that pro...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6A Window Into Parkinson's Disease 2Inside Myanmar 3A California Relief Organization Bypasses Bureaucratic Barriers Has Aid Workers in Myanmar 18991 1Air Methods Corporation Confirms Fatal Accident in Wisconsin 18988 116th Annual Komen Pittsburgh Race for the Cure 28R 29 Winners Announced 18986 116th Annual Komen Pittsburgh Race for the Cure 28R 29 Winners Announced 18986 2A new gene trigger for pregnancy disorder identified 3261 1A new gene trigger for pregnancy disorder identified 3261 2Inquire
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie
The IEC CL30 Series from Thermo delivers maximum convenience and exceptional value for your low-speed clinical applications. With its unique AUTO-LOCK rotor exchange system, user-friendly controls, a
The IEC CL10 from Thermo is the ideal centrifuge for your low-speed clinical applications. With its broad choice of rotors, user-friendly controls, and generous sample capacity, the IEC CL10 delivers
Medicine Products: